# Study: Tirzepatide (Zepbound) Cuts Prediabetes Progression to Type 2 by up to 94% ## Key Points: – Tirzepatide, also known as Zepbound, has shown promising results in reducing the progression from prediabetes to type 2 diabetes. – A recent study revealed that participants receiving tirzepatide had a significant 75% to 94% lower risk of developing type 2 diabetes compared to those receiving a placebo. – This new drug combines the actions of GLP-1 receptor agonist and GIP receptor agonist to effectively manage blood sugar levels and support weight loss. – The findings suggest that tirzepatide could be a groundbreaking treatment option for individuals at risk of developing type 2 diabetes. ## Hot Take: The results of the study on tirzepatide show great promise in reducing the progression from prediabetes to type 2 diabetes. This innovative drug could be a game-changer in managing blood sugar levels and promoting weight loss for those at risk. If you’re concerned about your prediabetes status, consider discussing tirzepatide with healthcare professionals to see if it may be a suitable option for you. *Contact Mindful Evolution on our website https://yourmindfulevolution.com or call or text us at 954-639-9960. Weight Loss Disclaimer: Individual results may vary. We offer telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.*